) The goal of the Clinical and Community Cancer Prevention and Control Program (CCCPCP) is to foster inter-disciplinary and inter-institutional research in cancer primary prevention, early detection, and treatment outcome studies in order to reduce the future incidence and death rates from cancer in Colorado, the Rocky Mountain Region, and the Nation. Research projects include phase III clinical trials of chemoprevention, screening, and behavioral interventions, and community-based studies of cancer prevention and cancer outcomes. The CCCPC Program is under the direction of Dr. Al Marcus (Acting CCCPC Program Leader), who is assisted by Mr. Kyle Osborn (DCPC Administrator). The CCCPCP includes 56 investigators (30 full members and 26 associate members) representing ten departments and centers in the University of Colorado Schools of Medicine and Nursing and several UCCC collaborating institutions, including the AMC Cancer Research Center. In 1999, CCCPC members have 61 grants and $7.7 million in direct costs in extramural support, including 28 grants and $5.5 million in direct costs from the National Cancer Institute. Over the past five years there has been an increase in the collaborations between UCCC members at the UCHSC and at the AMC, the Colorado Department of Public Health and Environment, the Colorado Foundation for Medical Care, and the other cancer centers in this region (New Mexico, Arizona, Utah). We expect even greater inter-institutional collaboration in the future as we continue to further develop a broad-based research program with an emphasis on the translation of behavioral and clinical research findings for the benefit of people in Colorado, the Rocky Mountain Region, and the Nation. This work will be supported by the new Survey Research Core and the developing cores in Health Communications and Recruitment/Retention. Recruitment are planned for a new CCCPC Program Leader, and for investigators in psychosocial oncology, community cancer research, and outcomes research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-15S1
Application #
6664434
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236

Showing the most recent 10 out of 1634 publications